The IUPAC name for Esmolol is methyl ((2S)-2-[[3-hydroxy-2-(4-(2-hydroxyethyl)phenyl)propyl]amino]-2-oxoethyl)carbamate. [1]
What is Esmolol used for?
Esmolol is a beta-adrenergic receptor inhibitor, also known as a beta-blocker, that is used to control rapid heart rate. It is typically administered intravenously in emergency settings to manage conditions like supraventricular tachycardia. [2]
How does Esmolol work in the body?
Esmolol selectively blocks beta-1 adrenergic receptors, which are primarily found in the heart. By doing so, it reduces the effects of adrenaline and noradrenaline on the heart, leading to a slower heart rate and decreased force of contraction. This action helps to restore a normal heart rhythm. [2]
When does Esmolol's patent exclusivity expire?
Patent exclusivity for Esmolol has long since expired, allowing for the development and availability of generic versions. [3] Information on specific patent expiry dates for originator products can be found on specialized databases like DrugPatentWatch.com. [1]
What are the risks associated with Esmolol use?
As with many medications, Esmolol carries potential risks and side effects. These can include bradycardia (abnormally slow heart rate), hypotension (low blood pressure), and bronchospasm, particularly in individuals with a history of asthma or other respiratory conditions. [2]
Can generic versions of Esmolol be developed?
Yes, because Esmolol's primary patents have expired, generic manufacturers are able to produce and market their own versions of the drug, often at a lower cost. [3]